Clinical Trials Logo

Clinical Trial Summary

evaluation of targeted axillary lymph node dissection in node positive breast cancer patients post neo adjuvant therapy


Clinical Trial Description

Targeted axillary dissection (TAD) is a novel technique in the field of surgical oncology. During TAD, patients with node-positive breast cancer who clinically responded to neoadjuvant chemotherapy undergo resection of a previously proven metastatic node together with sentinel lymph node dissection (SLND). Compared to sentinel lymph node dissection (SLND), axillary lymph node dissection [ALND] is associated with increased morbidity, higher rates of lymphedema, paraesthesia, sensory loss in the arm, and impairment in shoulder function. Patients undergoing SLND have fewer infections and a better quality of life, so axillary dissection has been largely replaced by SLND in early-stage breast cancer. Targeted axillary dissection (TAD) is an innovative surgical procedure that emerged in an attempt to further decrease the false negative results of SLND. Breast cancer patients suitable for neoadjuvant systemic therapy [NAST] with node-positive disease (N1,N2) were assessed by the multi-disciplinary team and if potentially eligible for TAD, a metallic marker[clip] is inserted in the suspicious node prior to neoadjuvant therapy. The procedure is performed together with SLND using a single-tracer technique. Towards the end of NAST, a progress ultrasound and mammogram are performed to assess the breast and axillary response, Clip position within node is confirmed. A standard surgical approach for sentinel lymph node dissection [SLND] is used for TAD, Patent blue dye is administered intraoperatively. dissection down to the localized node is performed. node contained the clip is subsequently sent for histology. Any residual sentinel nodes or palpable abnormal nodes are excised and examined separately. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05676866
Study type Interventional
Source Assiut University
Contact Omar Abd. Mahmoud, Resident doc
Phone 01098386293
Email omarico877@gmail.com
Status Not yet recruiting
Phase Phase 4
Start date December 1, 2023
Completion date August 1, 2025

See also
  Status Clinical Trial Phase
Recruiting NCT04039893 - MUltimodal Targeted Axillary Surgery N/A
Not yet recruiting NCT05970107 - Axillary Node Dissection w or w/o LVB in Node Positive Breast Cancer Patients N/A
Recruiting NCT04826211 - Axillary Staging in Node Positive Breast Cancer Patients Receiving PST. SNB vs PET/MRI N/A
Recruiting NCT05462457 - TAD in Primary Breast Cancer With Initially ≥ 3 Suspicious Lymph Nodes
Recruiting NCT05333328 - OFS in Premenopausal Node+ Breast Cancer With Low Genomic Risk Phase 4
Recruiting NCT03513614 - Tailored Axillary Surgery With or Without Axillary Lymph Node Dissection Followed by Radiotherapy in Patients With Clinically Node-positive Breast Cancer (TAXIS) N/A
Active, not recruiting NCT02515110 - Hypofractionated Regional Nodal Irradiation Clinical Trial for Women With Breast Cancer N/A